2024-511388-27-04CompletedPhase 2
Add-on Clioquinol in drug-resistant epilepsy: an exploratory study
Source: EU CTIS (euclinicaltrials.eu) · Last updated 29 Oct 2025
Brief summary (registry, in English)
To study whether add-on clioquinol decreases the seizure frequency and severity in patients with drug-resistant epilepsy.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (actual)
- First submitted
- 8 Jul 2024
- Start date
- 16 Jul 2024
- Lead sponsor
- UZ Leuven
- Diseases
- Epilepsy
- EU CT number
- 2024-511388-27-04
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 20
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Who cannot take part
Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.
Other
- Presence of C609T NQO1 SNP after SNP analysis of NQO1 based on a blood sample during baseline visit (visit 1) by Genomics Core
- Asian etnicity
- Abnormal low blood level of vitamin B12 or Zn
Who the study is looking for
- Drug-resistant epilepsy: ≥ 4 seizures in the 2 week prospective period (baseline) before visit 2, not all (4) seizures observed in 1 of the 2 weeks. Baseline period can be extended with 1 or 2 weeks.
- Age ≥ 12 years and < 35 years at time of inclusion
- Drug-resistant epilepsy: before inclusion failure of at least 2 AEDs
- The patient is at the moment of inclusion on max 4 anti-epileptic drugs (VNS and ketogenic diet not included)
- Well defined epilepsy history with convulsive seizures (with observable and countable motor component)
Age in the registry: - to 64 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| UZ Leuven Coordinator of this site? Confirm its status | Leuven | Belgium | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.